GLPwatch
Papers (10410)
Page 145 of 174, ranked by citation count.
- Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
- In brief: Semaglutide (Wegovy) for weight loss in children.
- Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.
- Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
- Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.
- A Systemic Review of Pharmacological Management of Pediatric Obesity.
- Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.
- A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.
- Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.
- Gliptins, exenatide, liraglutide: "intestinal obstruction".
- Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review.
- Tirzepatide for type 2 diabetes.
- Exendin-4 Prevents oxLDL-Induced upregulation of TREM2 and attenuates foam cell formation and inflammation in Macrophages.
- Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.
- Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
- The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.
- Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury.
- Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects.
- Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
- The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.
- Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.
- Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems.
- Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
- GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.
- Exploring novel protective role of semaglutide in 5-fluorouracil-induced hepatotoxicity: Insights into phosphorylated CREB, PINK1/Parkin-mediated mitophagy, and NF-κB/NLRP3 pathways.
- How to reset metabolic setpoint in obesity management.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Current challenges in type 2 diabetes.
- Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.
- Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.
- Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
- Effects of Dulaglutide on Ectopic Fat Deposition in Chronic Kidney Disease (CKD): A Pilot and Feasibility Study (GLIMP).
- The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.
- Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).
- Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure.
- Reassessing retinopathy risk with tirzepatide therapy.
- Tirzepatide as adjunct to insulin for the treatment of type 1 diabetes.
- Re-evaluating GLP-1 receptor agonist-associated changes in copeptin.
- Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
- A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models.
- Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821.
- The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA<sub>1c(v)</sub>-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al.
- iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.
- Individual Variability in the Cardiometabolic Response to Tirzepatide: Moving Beyond the Average.
- Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.
- Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge.
- Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.
- Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
- [Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].
- GLP-1 receptor agonists as pharmacological treatment for obesity after spinal cord injury: clinical considerations.
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
- Two new GLP-1 receptor agonists for diabetes.
- AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update.
- Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
- Functional hydrophilic polystyrene beads with uniformly size and high cross-linking degree facilitated rapid separation of exenatide.
- Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
- Which Drug Will "Lead" in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?
- [Pharmacotherapy for obesity].
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.